Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma
Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy do...
Gespeichert in:
| Veröffentlicht in: | Journal of veterinary internal medicine 2009-09, Vol.23 (5), p.1064-1070 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1070 |
|---|---|
| container_issue | 5 |
| container_start_page | 1064 |
| container_title | Journal of veterinary internal medicine |
| container_volume | 23 |
| creator | Lurie, D.M Gordon, I.K Theon, A.P Rodriguez, C.O Suter, S.E Kent, M.S |
| description | Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)‐based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
Animals: Thirty‐eight client‐owned animals diagnosed with multicentric lymphoma.
Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
Results: The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1‐, 2‐, and 3‐year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1‐, 2‐, and 3‐year survival rates were 66, 47, and 44%.
Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2‐week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma. |
| doi_str_mv | 10.1111/j.1939-1676.2009.0353.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_proquest_miscellaneous_902330573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902330573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5073-f660835f15bbbc5ebdc0b78ea65224e783376a449884727bf2cc90761624be933</originalsourceid><addsrcrecordid>eNqNkF1v0zAUhi3ExMrgLzDfcZXgj9iOJW6gg65bx6R1G5eWkzjUJYk7O9Wafz9HqcYtvvHR0fOeo_MAcI5RiuP7sk2xpDLBXPCUICRTRBlND2_A7LX_FsxQLnHCeYZOwfsQtggRxph4B06x5ERkgszA09o87U3XW93AlXtOLlww8E73Bl7qpk6-u2qAS-91ZXVvXQd1V8H5xrSu3xivdwOsnYexhvfe6L6Nk6Cr4Vx3tjPwZt_0tow9b0u4GtrdxrX6AzipdRPMx-N_Bh5-_rifXyar28Vy_m2VlAwJmtSco5yyGrOiKEpmiqpEhciN5oyQzIicUsF1lsk8j4eIoiZlKZHgmJOsMJLSM_B5mrvzLp4YetXaUJqm0Z1x-6AkIpQiJkZSTGTpXQje1Grnbav9oDBSo261VaNWNWpVo2416laHmPx03LEvWlP9yx39RuDrBDzbxgz_O1ddPS5vYhXjyRS3oTeH17j2fxUXVDD1-9dCrbNFLsT6UV1H_nzia-2U_uNtUA9rgjBFmOcMSUZfADHYpnc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902330573</pqid></control><display><type>article</type><title>Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma</title><source>Wiley Online Library Open Access</source><creator>Lurie, D.M ; Gordon, I.K ; Theon, A.P ; Rodriguez, C.O ; Suter, S.E ; Kent, M.S</creator><creatorcontrib>Lurie, D.M ; Gordon, I.K ; Theon, A.P ; Rodriguez, C.O ; Suter, S.E ; Kent, M.S</creatorcontrib><description>Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)‐based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
Animals: Thirty‐eight client‐owned animals diagnosed with multicentric lymphoma.
Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
Results: The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1‐, 2‐, and 3‐year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1‐, 2‐, and 3‐year survival rates were 66, 47, and 44%.
Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2‐week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.</description><identifier>ISSN: 0891-6640</identifier><identifier>EISSN: 1939-1676</identifier><identifier>DOI: 10.1111/j.1939-1676.2009.0353.x</identifier><identifier>PMID: 19627472</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; chemotherapy ; combination drug therapy ; Combination therapy ; Combined Modality Therapy ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Dog Diseases - drug therapy ; Dog Diseases - pathology ; Dog Diseases - radiotherapy ; Dogs ; Dose-Response Relationship, Radiation ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Efficacy ; Female ; Hematocrit - veterinary ; Hemibody Irradiation - methods ; Hemibody Irradiation - veterinary ; Immunophenotyping - veterinary ; Kaplan-Meier Estimate ; lymphoma ; Lymphoma - drug therapy ; Lymphoma - pathology ; Lymphoma - radiotherapy ; Lymphoma - veterinary ; Male ; Prednisone - administration & dosage ; Prednisone - adverse effects ; radiotherapy ; Retrospective Studies ; Vincristine - administration & dosage ; Vincristine - adverse effects</subject><ispartof>Journal of veterinary internal medicine, 2009-09, Vol.23 (5), p.1064-1070</ispartof><rights>Copyright © 2009 by the American College of Veterinary Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5073-f660835f15bbbc5ebdc0b78ea65224e783376a449884727bf2cc90761624be933</citedby><cites>FETCH-LOGICAL-c5073-f660835f15bbbc5ebdc0b78ea65224e783376a449884727bf2cc90761624be933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1939-1676.2009.0353.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1939-1676.2009.0353.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,11562,27924,27925,45574,45575,46052,46476</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1939-1676.2009.0353.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19627472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lurie, D.M</creatorcontrib><creatorcontrib>Gordon, I.K</creatorcontrib><creatorcontrib>Theon, A.P</creatorcontrib><creatorcontrib>Rodriguez, C.O</creatorcontrib><creatorcontrib>Suter, S.E</creatorcontrib><creatorcontrib>Kent, M.S</creatorcontrib><title>Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma</title><title>Journal of veterinary internal medicine</title><addtitle>J Vet Intern Med</addtitle><description>Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)‐based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
Animals: Thirty‐eight client‐owned animals diagnosed with multicentric lymphoma.
Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
Results: The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1‐, 2‐, and 3‐year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1‐, 2‐, and 3‐year survival rates were 66, 47, and 44%.
Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2‐week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>chemotherapy</subject><subject>combination drug therapy</subject><subject>Combination therapy</subject><subject>Combined Modality Therapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dog Diseases - drug therapy</subject><subject>Dog Diseases - pathology</subject><subject>Dog Diseases - radiotherapy</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Efficacy</subject><subject>Female</subject><subject>Hematocrit - veterinary</subject><subject>Hemibody Irradiation - methods</subject><subject>Hemibody Irradiation - veterinary</subject><subject>Immunophenotyping - veterinary</subject><subject>Kaplan-Meier Estimate</subject><subject>lymphoma</subject><subject>Lymphoma - drug therapy</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - radiotherapy</subject><subject>Lymphoma - veterinary</subject><subject>Male</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - adverse effects</subject><subject>radiotherapy</subject><subject>Retrospective Studies</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><issn>0891-6640</issn><issn>1939-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF1v0zAUhi3ExMrgLzDfcZXgj9iOJW6gg65bx6R1G5eWkzjUJYk7O9Wafz9HqcYtvvHR0fOeo_MAcI5RiuP7sk2xpDLBXPCUICRTRBlND2_A7LX_FsxQLnHCeYZOwfsQtggRxph4B06x5ERkgszA09o87U3XW93AlXtOLlww8E73Bl7qpk6-u2qAS-91ZXVvXQd1V8H5xrSu3xivdwOsnYexhvfe6L6Nk6Cr4Vx3tjPwZt_0tow9b0u4GtrdxrX6AzipdRPMx-N_Bh5-_rifXyar28Vy_m2VlAwJmtSco5yyGrOiKEpmiqpEhciN5oyQzIicUsF1lsk8j4eIoiZlKZHgmJOsMJLSM_B5mrvzLp4YetXaUJqm0Z1x-6AkIpQiJkZSTGTpXQje1Grnbav9oDBSo261VaNWNWpVo2416laHmPx03LEvWlP9yx39RuDrBDzbxgz_O1ddPS5vYhXjyRS3oTeH17j2fxUXVDD1-9dCrbNFLsT6UV1H_nzia-2U_uNtUA9rgjBFmOcMSUZfADHYpnc</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Lurie, D.M</creator><creator>Gordon, I.K</creator><creator>Theon, A.P</creator><creator>Rodriguez, C.O</creator><creator>Suter, S.E</creator><creator>Kent, M.S</creator><general>Blackwell Publishing Inc</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200909</creationdate><title>Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma</title><author>Lurie, D.M ; Gordon, I.K ; Theon, A.P ; Rodriguez, C.O ; Suter, S.E ; Kent, M.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5073-f660835f15bbbc5ebdc0b78ea65224e783376a449884727bf2cc90761624be933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>chemotherapy</topic><topic>combination drug therapy</topic><topic>Combination therapy</topic><topic>Combined Modality Therapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dog Diseases - drug therapy</topic><topic>Dog Diseases - pathology</topic><topic>Dog Diseases - radiotherapy</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Efficacy</topic><topic>Female</topic><topic>Hematocrit - veterinary</topic><topic>Hemibody Irradiation - methods</topic><topic>Hemibody Irradiation - veterinary</topic><topic>Immunophenotyping - veterinary</topic><topic>Kaplan-Meier Estimate</topic><topic>lymphoma</topic><topic>Lymphoma - drug therapy</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - radiotherapy</topic><topic>Lymphoma - veterinary</topic><topic>Male</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - adverse effects</topic><topic>radiotherapy</topic><topic>Retrospective Studies</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lurie, D.M</creatorcontrib><creatorcontrib>Gordon, I.K</creatorcontrib><creatorcontrib>Theon, A.P</creatorcontrib><creatorcontrib>Rodriguez, C.O</creatorcontrib><creatorcontrib>Suter, S.E</creatorcontrib><creatorcontrib>Kent, M.S</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of veterinary internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Lurie, D.M</au><au>Gordon, I.K</au><au>Theon, A.P</au><au>Rodriguez, C.O</au><au>Suter, S.E</au><au>Kent, M.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma</atitle><jtitle>Journal of veterinary internal medicine</jtitle><addtitle>J Vet Intern Med</addtitle><date>2009-09</date><risdate>2009</risdate><volume>23</volume><issue>5</issue><spage>1064</spage><epage>1070</epage><pages>1064-1070</pages><issn>0891-6640</issn><eissn>1939-1676</eissn><abstract>Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy dose levels.
Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)‐based chemotherapy protocol is effective for the treatment of lymphoma in dogs.
Animals: Thirty‐eight client‐owned animals diagnosed with multicentric lymphoma.
Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy.
Results: The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1‐, 2‐, and 3‐year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1‐, 2‐, and 3‐year survival rates were 66, 47, and 44%.
Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2‐week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>19627472</pmid><doi>10.1111/j.1939-1676.2009.0353.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0891-6640 |
| ispartof | Journal of veterinary internal medicine, 2009-09, Vol.23 (5), p.1064-1070 |
| issn | 0891-6640 1939-1676 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902330573 |
| source | Wiley Online Library Open Access |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use chemotherapy combination drug therapy Combination therapy Combined Modality Therapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dog Diseases - drug therapy Dog Diseases - pathology Dog Diseases - radiotherapy Dogs Dose-Response Relationship, Radiation Doxorubicin - administration & dosage Doxorubicin - adverse effects Efficacy Female Hematocrit - veterinary Hemibody Irradiation - methods Hemibody Irradiation - veterinary Immunophenotyping - veterinary Kaplan-Meier Estimate lymphoma Lymphoma - drug therapy Lymphoma - pathology Lymphoma - radiotherapy Lymphoma - veterinary Male Prednisone - administration & dosage Prednisone - adverse effects radiotherapy Retrospective Studies Vincristine - administration & dosage Vincristine - adverse effects |
| title | Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A12%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20Low-Dose%20Rate%20Half-Body%20Irradiation%20and%20Chemotherapy%20for%20the%20Treatment%20of%20Canine%20Multicentric%20Lymphoma&rft.jtitle=Journal%20of%20veterinary%20internal%20medicine&rft.au=Lurie,%20D.M&rft.date=2009-09&rft.volume=23&rft.issue=5&rft.spage=1064&rft.epage=1070&rft.pages=1064-1070&rft.issn=0891-6640&rft.eissn=1939-1676&rft_id=info:doi/10.1111/j.1939-1676.2009.0353.x&rft_dat=%3Cproquest_24P%3E902330573%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902330573&rft_id=info:pmid/19627472&rfr_iscdi=true |